DR. JAMES ALONZO NELSON, M.D.
Medical Practice at Windermere Rd, Seattle, WA

6374670, Apr 23, 2002

Mar 13, 1995

08/402872

Francis A. Spelman - Seattle WA
Page Read - Seattle WA
N. Mani Prakash - Seattle WA
James A. Nelson - Seattle WA
Charles E. Pope - Seattle WA
Margaret Heitkemper - Seattle WA
James D. Rothermel - Seattle WA

University of Washington - Seattle WA

A61B 522

7337901

An apparatus ( ) and method of non-invasive monitoring of gut motility. An ingestible magnet ( M) is swallowed by the patient ( ) and then linear and rotational movement is directionally detected by an external compass ( ). In preferred form, movements of the magnet ( M) are recorded by a memory means ( ) and graphically presented ( ) over a period of predetermined time. An alternate embodiment includes multiple compasses (C C ) for directionally locating the magnet ( M) within the patient ( ).

6447539, Sep 10, 2002

Sep 15, 1997

08/929076

James A. Nelson - Seattle WA
Ascher Shmulewitz - Mercer Island WA
John Burton - Minnetonka MN

TransVascular, Inc. - Menlo Park CA

A61F 206

623 111, 128898, 606194, 604 9301

Methods and apparatus are provided for use in intraoperative and percutaneous procedures for supplying long-term retrograde perfusion of the myocardium via one or more conduits disposed between the left ventricle and the coronary venous vasculature. The conduits are of a selected size and number, and portions of the venous vasculature or coronary ostium are partially or completely occluded, to maintain a parameter related to the pressure attained in the venous vasculature to a value less than a predetermined value.

5824071, Oct 20, 1998

Feb 12, 1997

8/798700

James A. Nelson - Seattle WA
Ascher Shmulewitz - Mercer Island WA

Circulation, Inc. - Menlo Park CA

A61M 110

623 3

Apparatus and methods are provided for use in open surgical and transluminal methods for supplying long-term retrograde perfusion of the myocardium via a conduit disposed between the left ventricle and the coronary sinus. In a first method, an opening is formed between the left ventricle and the coronary sinus, and the coronary ostium is partially occluded using a stent that prevents the pressure in the coronary sinus from exceeding a predetermined value. In an alternative method, a first end of a conduit is inserted transeptally through the right atrium and obliquely into the posterior septal endocardium of the left ventricle via the posterior pyramidal space, while a second end of the conduit is inserted into the coronary sinus via the coronary ostium. A pressure-limiting valve is included in the conduit. In either method, the outlet from the left ventricle to the coronary sinus may include a one-way valve to prevent backflow from the coronary sinus into the left ventricle during cardiac diastole.

2010010, Apr 29, 2010

Jul 13, 2007

12/373854

James A. Nelson - Seattle WA, US

A61M 25/00, A61M 16/04, A61F 2/84

623 111, 604523, 12820714, 604544

An improved catheter is provided for insertion into a trachea, blood vessel, bladder or urinary tract of a patient. The self cleaning catheter can be easily inserted and removed from the patient without retained, solid components falling into a patient's trachea, blood vessels, bladder, or urinary tract when the catheter is removed from the patient. The self cleaning catheter has a flexible cylindrical sleeve on the exterior of a cylindrical member that can be withdrawn to the interior of the catheter prior to removal from the patient's body. Alternatively, the catheter has a design allowing an end of the catheter to fold inward on itself prior to removal from the patient's body.

5169944, Dec 8, 1992

Apr 12, 1991

7/685083

James A. Nelson - Seattle WA
Udo P. Schmiedl - Kirkland WA
Linnar L. Teng - Bothell WA
Jerry C. Bommer - Wellsville UT

Board of Regents of the University of Washington - Seattle WA

A61B 5055, C07D48722, G01N 2408

540145

Hepatobiliary magnetic resonance imaging of a human or animal subject is enhanced by enterally administering to the subject an effective amount of a lipophilic contrast enhancing agent. Representative contrast enhancing agents include manganese mesoporphyrin, manganese deuteroporphyrin, manganese pheophorbide and manganese pyrophenophoribide, and, when administered orally, an enteric delivery agent.